Bayer Pharma Aktiengesellschaft

Juliane Paul

Antje Margret Wengner

Ningshu Liu

Katja Haike

Described herein are pharmaceutical combinations and compositions comprising a) a 2,3-dihydroimidazo[1,2-c]quinazoline compound, or a salt thereof, and b) one more additional active agents. The pharmaceutical combinations described herein may be useful for treating non-Hodgkin's lymphoma (NHL), particularly 1st line, 2nd line, relapsed, refractory, indolent or aggressive non-Hodgkin's lymphoma (NHL); follicular lymphoma (FL); chronic lymphocytic leukemia (CLL); marginal zone lymphoma (MZL); diffuse large B-cell lymphoma (DLBCL); mantle cell lymphoma (MCL); transformed lymphoma (TL); or peripheral T-cell lymphoma (PTCL).

Use of substituted 2,3-dihydroimidazo[1,2-C]quinazolines for treating lymphomas

Described herein arc methods of treating non-Hodgkin's lymphoma (NHL), wherein the non-Hodgkin's lymphoma (NHL) is selected from the group consisting of 1st line, 2nd line, relapsed, refractory, indolent or aggressive non-Hodgkin's lymphoma (NHL); follicular lymphoma (FL); chronic lymphocytic leukemia (CLL); marginal zone lymphoma (MZL); diffuse large B-cell lymphoma (DLBCL); mantle cell lymphoma (MCL); transformed lymphoma (TL); and peripheral T-cell lymphoma (PTCL). comprising administering to a patient in need thereof a 2,3-dihydroimidazo[1,2-c] quinazolinc compound, or a salt thereof.

Growing community of inventors

Berlin, Germany

Juliane Paul